There were two developments in Amarin’s (AMRN) fight to keep generic versions of Vascepa (icosapent ethyl) from launching that we first reported on last week. First, we now find a New Clinical Investigation Exclusivity for the drug’s expanded cardiovascular risk indication on Vascepa’s FDA Orange Book listing. This is the indication supported by the Reduce-It trial. It is our understanding that this provides 3 years of exclusivity, in which time the FDA will not approve a generic Vascepa for this expanded cardiovascular risk reduction indication. Second, in its Hatch-Waxman (generic drug) Vascepa